Is Attruby's Accelerating Launch and Star-Studded Awareness Campaign Altering The Investment Case For BridgeBio Pharma (BBIO)? [Yahoo! Finance]
BridgeBio Pharma, Inc. (BBIO)
Last bridgebio pharma, inc. earnings: 3/2 08:29 am
Check Earnings Report
Company Research
Source: Yahoo! Finance
and prescribers, supported by compelling clinical efficacy data, particularly in treatment-naive patients. The company has also rolled out a national ATTR-CM health education campaign featuring Morgan Freeman and Howard “H” White, a move that both raises disease awareness and underscores BridgeBio's ambition to build a meaningful commercial foothold by marketing and selling its own medicines. Next, we'll examine how Attruby's accelerating launch, supported by this high-profile awareness campaign, may reshape BridgeBio's investment narrative. Uncover the next big thing with 24 elite penny stocks that balance risk and reward. BridgeBio Pharma Investment Narrative Recap To own BridgeBio today, you need to believe Attruby can support a sustainable commercial franchise while the late-stage rare-disease pipeline matures. The strong early launch and high-profile ATTR-CM awareness campaign are positive for near-term Attruby demand, but they do not remove the core risks: heavy relian
Show less
Read more
Impact Snapshot
Event Time:
BBIO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BBIO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BBIO alerts
High impacting BridgeBio Pharma, Inc. news events
Weekly update
A roundup of the hottest topics
BBIO
News
- BridgeBio to Report First Quarter 2026 Financial Results and Commercial Updates on May 7, 2026 at 4:30 pm ETGlobeNewswire
- BridgeBio Pharma (BBIO) had its price target raised by Truist Financial Corporation from $95.00 to $102.00. They now have a "buy" rating on the stock.MarketBeat
- BridgeBio (BBIO) Q2 2025 Earnings Transcript [Globe and Mail, The (Toronto, Canada)]Globe and Mail, The
- BridgeBio (BBIO) Q2 2025 Earnings Transcript [Yahoo! Finance]Yahoo! Finance
- BridgeBio Pharma (BBIO) had its "outperform" rating reaffirmed by Mizuho. They now have a $106.00 price target on the stock.MarketBeat
BBIO
Earnings
- 2/24/26 - Miss
BBIO
Sec Filings
- 4/24/26 - Form DEFA14A
- 4/24/26 - Form ARS
- 4/24/26 - Form DEF
- BBIO's page on the SEC website